Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiandrogenic drugs

D G McLeod1

  • 1Urology Service, Walter Reed Army Medical Center, Washington, DC.

Cancer
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Antiandrogenic drugs, or androgen-receptor antagonists, are emerging as a key treatment for metastatic prostate cancer. Ongoing studies explore their use alone versus standard therapies, suggesting an expanding role in prostate cancer management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression.

Prostate cancer and prostatic diseases·2012
Same author

Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.

Prostate cancer and prostatic diseases·2010
Same author

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Prostate cancer and prostatic diseases·2010
Same author

Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.

Prostate cancer and prostatic diseases·2009
Same author

Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?

Journal of clinical pathology·2008
Same author

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Oncogene·2008
Same journal

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

Cancer·2026
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Prostate cancer is the most common cancer in American men.
  • Approximately 50% of newly diagnosed prostate cancer cases present as metastatic disease.

Purpose of the Study:

  • To review the role and mechanisms of antiandrogenic drugs in prostate cancer treatment.
  • To discuss the current and potential future applications of these agents.

Main Methods:

  • Review of antiandrogenic drugs, classified as steroidal and nonsteroidal.
  • Description of their mechanism of action: blocking androgen receptors.
  • Mention of specific drugs like cyproterone acetate, megestrol acetate, flutamide, Casodex, and nilutamide.

Main Results:

  • Antiandrogenics have been utilized in numerous clinical trials.

Related Experiment Videos

  • These agents have been employed as monotherapy and in combination with orchiectomy or LHRH agonists.

    • Conclusions:

    • Antiandrogens are primarily used with castration for maximal androgen deprivation.
    • Clinical studies are evaluating antiandrogens as standalone therapy.
    • Antiandrogens are expected to play an increasing role in treating prostate cancer, including metastatic forms.